MannKind Corporation to Hold 2020 Fourth Quarter and Full Year Financial Results Conference Call on February 25, 2021
February 18 2021 - 9:00AM
MannKind Corporation (NASDAQ:MNKD) will release
its 2020 fourth quarter and full year financial results and its
management will host a conference call to discuss the financial
results and corporate updates at 9:00 AM (Eastern Time) on
Thursday, February 25, 2021.
Presenting from the Company will be its Chief
Executive Officer, Michael Castagna and Chief Financial Officer,
Steven Binder.
Those interested in listening to the conference
call live via the Internet may do so by visiting the Company's
website at http://www.mannkindcorp.com under News &
Events.
A telephone replay of the call will be
accessible for approximately 14 days following completion of the
call by dialing (844) 512-2921 or (412) 317-6671 and use the
participant passcode: 7174315#. A replay will also be available on
MannKind's website for 14 days.
About MannKind
CorporationMannKind Corporation (NASDAQ: MNKD) focuses on
the development and commercialization of inhaled therapeutic
products for patients with endocrine and orphan lung diseases.
MannKind is currently commercializing Afrezza® (insulin human)
Inhalation Powder, the Company’s first FDA-approved product and the
only inhaled ultra rapid-acting mealtime insulin in the United
States, where it is available by prescription from pharmacies
nationwide. Afrezza is also available by prescription in Brazil
where it is commercialized by the Company’s partner Biomm SA.
MannKind is headquartered in Westlake Village, California, and has
a state-of-the art manufacturing facility in Danbury, Connecticut.
The Company also employs field sales and medical representatives
across the U.S. For further information, visit
www.mannkindcorp.com.
Company Contact: Phone: (818) 661-5000 Email:
ir@mannkindcorp.com
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Mar 2024 to Apr 2024
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Apr 2023 to Apr 2024